Advertisement
CORT vs OPK
Which Stock Would AI Choose? Corcept Therapeutics (CORT) vs. OPKO Health (OPK) Stock Comparison
Key Takeaways
- Corcept Therapeutics (CORT) has delivered substantial year-to-date gains driven by pipeline advancements and revenue growth, while OPKO Health (OPK) has shown more limited movement in recent market activity.
- Both companies operate in the healthcare sector but differ in focus, with CORT centered on cortisol modulation therapies and OPK spanning diagnostics and pharmaceuticals.
- Recent analyst attention and regulatory updates have supported sentiment around CORT, contrasting with comparatively quieter developments for OPK.
- Market capitalization and trading volume reflect CORT’s larger scale relative to OPK in current conditions.
- Relative performance highlights contrasts in momentum, with CORT exhibiting stronger recent price appreciation amid broader healthcare volatility.
- Sector exposure to biotechnology innovation positions both for potential catalysts, though risk profiles vary based on development-stage maturity.
Introduction
This comparison examines Corcept Therapeutics (CORT) and OPKO Health (OPK), two healthcare equities with distinct profiles in drug development and diagnostics. Investors and traders evaluating biotechnology opportunities may find this analysis relevant for assessing relative positioning, momentum, and sector-specific dynamics. The review draws on observable market data and recent developments to highlight contrasts without forecasting outcomes.
CORT Overview and Recent Performance
Corcept Therapeutics focuses on therapies targeting cortisol modulation, primarily for endocrine disorders such as Cushing’s syndrome. In recent weeks, the stock has demonstrated notable appreciation, trading near the upper end of its 52-week range amid positive regulatory and clinical updates. Key influences include resubmission of a new drug application for relacorilant and raised full-year revenue guidance, which have contributed to improved market sentiment. Broader analyst commentary has reflected bullish views in select instances, supporting relative outperformance compared to broader market indices during the period.
OPK Overview and Recent Performance
OPKO Health engages in pharmaceutical development and diagnostic services across multiple therapeutic areas. Recent market activity has shown more modest price movements, with the stock reflecting limited immediate catalysts in public disclosures. The company maintains a diversified approach that includes established diagnostic platforms, though sentiment appears steadier relative to higher-volatility peers. Performance in the recent period has aligned with broader small-cap healthcare trends, without standout drivers emerging from regulatory or earnings events in the immediate timeframe.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of AI trading bots optimized for prevailing market conditions. While Tickeron offers hundreds of AI Trading Bots capable of trading thousands of different tickers, only those demonstrating strong suitability and performance metrics earn placement in this trending section. Available bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker sets, with historical win rates and returns varying by configuration—often falling in ranges that reflect diverse risk-reward profiles. This resource provides traders with data-driven insights into automated strategies. Explore the full selection on the Trending AI Robots page for additional details.
Head-to-Head Comparison
Corcept Therapeutics (CORT) and OPKO Health (OPK) differ markedly in business models, with CORT emphasizing specialized endocrine treatments and OPK maintaining broader exposure across diagnostics and multiple drug programs. Growth drivers for CORT center on late-stage pipeline milestones and commercial expansion, whereas OPK’s trajectory ties more closely to diagnostic revenue stability and earlier-stage development. Recent momentum favors CORT, evidenced by stronger price appreciation and analyst upgrades, while OPK has experienced comparatively contained volatility. Risk factors include clinical and regulatory uncertainties for both, though CORT’s larger market capitalization may imply different liquidity dynamics than OPK’s smaller scale. Sector exposure remains healthcare-focused for each, with market sentiment reflecting CORT’s higher visibility in recent activity versus OPK’s steadier profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability indicators, and relative positioning in recent market data, Tickeron’s AI would currently assign a probabilistic preference toward Corcept Therapeutics (CORT). This assessment rests on stronger momentum signals and catalyst visibility compared to OPKO Health (OPK), though outcomes remain subject to evolving conditions and individual risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Hold and OPK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CORT’s FA Score shows that 1 FA rating(s) are green whileOPK’s FA Score has 0 green FA rating(s).
- CORT’s FA Score: 1 green, 4 red.
- OPK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CORT’s TA Score shows that 4 TA indicator(s) are bullish while OPK’s TA Score has 6 bullish TA indicator(s).
- CORT’s TA Score: 4 bullish, 4 bearish.
- OPK’s TA Score: 6 bullish, 5 bearish.
Price Growth
CORT (@Biotechnology) experienced а +5.35% price change this week, while OPK (@Medical Specialties) price change was +2.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.96%. For the same industry, the average monthly price growth was +2.95%, and the average quarterly price growth was +1952.21%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.15%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +3.41%.
Reported Earning Dates
CORT is expected to report earnings on Jul 29, 2026.
OPK is expected to report earnings on Jul 27, 2026.
Industries' Descriptions
@Biotechnology (+3.96% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+0.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| CORT | OPK | CORT / OPK | |
| Capitalization | 10.2B | 944M | 1,081% |
| EBITDA | -6.19M | -34.67M | 18% |
| Gain YTD | 174.023 | -3.175 | -5,482% |
| P/E Ratio | 272.46 | N/A | - |
| Revenue | 769M | 581M | 132% |
| Total Cash | 338M | 342M | 99% |
| Total Debt | 9.64M | 397M | 2% |
CORT | OPK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 53 | 100 | |
SMR RATING 1..100 | 80 | 96 | |
PRICE GROWTH RATING 1..100 | 35 | 72 | |
P/E GROWTH RATING 1..100 | 5 | 98 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OPK's Valuation (54) in the Biotechnology industry is somewhat better than the same rating for CORT (100) in the Pharmaceuticals Other industry. This means that OPK’s stock grew somewhat faster than CORT’s over the last 12 months.
CORT's Profit vs Risk Rating (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for OPK (100) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than OPK’s over the last 12 months.
CORT's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as OPK (96) in the Biotechnology industry. This means that CORT’s stock grew similarly to OPK’s over the last 12 months.
CORT's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for OPK (72) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than OPK’s over the last 12 months.
CORT's P/E Growth Rating (5) in the Pharmaceuticals Other industry is significantly better than the same rating for OPK (98) in the Biotechnology industry. This means that CORT’s stock grew significantly faster than OPK’s over the last 12 months.
| CORT | OPK | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 69% | 4 days ago 82% |
| Stochastic ODDS (%) | 4 days ago 73% | 4 days ago 81% |
| Momentum ODDS (%) | 4 days ago 82% | 4 days ago 76% |
| MACD ODDS (%) | 4 days ago 79% | 4 days ago 83% |
| TrendWeek ODDS (%) | 4 days ago 79% | 4 days ago 74% |
| TrendMonth ODDS (%) | 4 days ago 80% | 4 days ago 77% |
| Advances ODDS (%) | 7 days ago 83% | 7 days ago 73% |
| Declines ODDS (%) | 15 days ago 65% | 5 days ago 81% |
| BollingerBands ODDS (%) | N/A | 4 days ago 83% |
| Aroon ODDS (%) | 4 days ago 74% | 4 days ago 70% |
Advertisement